Alexion Pharmaceuticals (ALXN) PT Raised to $151.00 at Morgan Stanley
Alexion Pharmaceuticals (NASDAQ:ALXN) had its price objective lifted by Morgan Stanley from $148.00 to $151.00 in a research note published on Friday morning. The firm currently has an overweight rating on the biopharmaceutical company’s stock.
ALXN has been the topic of several other reports. Piper Jaffray Companies reiterated an overweight rating and issued a $170.00 price target on shares of Alexion Pharmaceuticals in a report on Monday, October 23rd. Stifel Nicolaus reduced their price target on Alexion Pharmaceuticals from $165.00 to $159.00 and set a buy rating on the stock in a report on Tuesday, October 24th. Royal Bank of Canada increased their price target on Alexion Pharmaceuticals to $166.00 in a report on Tuesday, October 24th. Zacks Investment Research upgraded Alexion Pharmaceuticals from a hold rating to a buy rating and set a $144.00 price target on the stock in a report on Tuesday, October 31st. Finally, TheStreet downgraded Alexion Pharmaceuticals from a b- rating to a c+ rating in a report on Friday, November 10th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and twenty-one have issued a buy rating to the company. The stock currently has a consensus rating of Buy and an average price target of $153.14.
Shares of Alexion Pharmaceuticals (ALXN) traded up $0.13 during mid-day trading on Friday, reaching $108.60. The company’s stock had a trading volume of 3,023,599 shares, compared to its average volume of 1,970,000. Alexion Pharmaceuticals has a fifty-two week low of $96.18 and a fifty-two week high of $149.34. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.51 and a current ratio of 3.10. The stock has a market capitalization of $24,290.00, a P/E ratio of 55.13, a PEG ratio of 0.91 and a beta of 1.16.
In related news, SVP Heidi L. Wagner sold 655 shares of the stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $117.26, for a total value of $76,805.30. Following the transaction, the senior vice president now owns 32,635 shares of the company’s stock, valued at $3,826,780.10. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Ludwig Hantson sold 2,553 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $121.63, for a total value of $310,521.39. Following the completion of the transaction, the chief executive officer now directly owns 36,172 shares in the company, valued at approximately $4,399,600.36. The disclosure for this sale can be found here. In the last three months, insiders sold 28,930 shares of company stock worth $3,378,199. 4.35% of the stock is owned by insiders.
A number of large investors have recently made changes to their positions in the stock. Ameriprise Financial Inc. grew its stake in Alexion Pharmaceuticals by 3.5% in the third quarter. Ameriprise Financial Inc. now owns 6,390,301 shares of the biopharmaceutical company’s stock worth $896,491,000 after purchasing an additional 215,005 shares in the last quarter. Jennison Associates LLC grew its stake in Alexion Pharmaceuticals by 720.0% in the third quarter. Jennison Associates LLC now owns 5,332,636 shares of the biopharmaceutical company’s stock worth $748,116,000 after purchasing an additional 4,682,336 shares in the last quarter. UBS Asset Management Americas Inc. boosted its position in Alexion Pharmaceuticals by 10.3% during the 4th quarter. UBS Asset Management Americas Inc. now owns 1,871,548 shares of the biopharmaceutical company’s stock valued at $223,818,000 after acquiring an additional 174,606 shares in the last quarter. Wells Fargo & Company MN boosted its position in Alexion Pharmaceuticals by 32.7% during the 3rd quarter. Wells Fargo & Company MN now owns 1,558,531 shares of the biopharmaceutical company’s stock valued at $218,647,000 after acquiring an additional 383,713 shares in the last quarter. Finally, Bank of Montreal Can boosted its position in Alexion Pharmaceuticals by 21.4% during the 4th quarter. Bank of Montreal Can now owns 1,521,834 shares of the biopharmaceutical company’s stock valued at $181,998,000 after acquiring an additional 268,053 shares in the last quarter. 94.04% of the stock is currently owned by institutional investors.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.